Benjamin L. Schlechter
YOU?
Author Swipe
View article: 8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases
8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases Open
View article: Figure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Figure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Supplementary Figure S1: Efficacy data of pembrolizumab and trebananib.
View article: Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Table S3
View article: Table S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Table S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Table S2
View article: Figure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Figure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Supplementary Figure S3: Tumor immune microenvironment of colorectal cancer cohort.
View article: Figure S4 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Figure S4 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Supplementary Figure S4: Tumor immune microenvironment in a colorectal cancer patient with acquired resistance to pembrolizumab and trebananib.
View article: Data from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Data from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Ovarian cancers and microsatellite stable (MSS) colorectal cancers are insensitive to anti–programmed cell death 1 (PD-1) immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggest a relationship between immun…
View article: Table S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Table S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Table S1
View article: Figure S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Figure S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Supplementary Figure S2: Treatment history of each patient with metastatic CRC with ERBB2 amplification and durable response to trial therapy in patient 32 (a) and patient 5 (b).
View article: Table S4 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Table S4 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Table S4
View article: Figure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Figure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer Open
Supplementary Figure S5: Survival by ERBB2 status.
View article: 1472 A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors
1472 A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors Open
View article: Supplementary Table S15 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S15 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
List Of Germline Variants In Pancreatic Cancer Cohort
View article: Supplementary Table S12 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S12 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Genomic comparison between KRAS WT Pancreatic cancers with and without MAPK alterations
View article: Supplementary Table S11 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S11 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
BRAF KRAS co-occurence
View article: Supplementary Figure S7 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S7 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Copy number gains in MAPK genes are infrequent in KRAS WT, MAPK Negative pancreatic cancer
View article: Supplementary Table S1 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S1 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
List of genes covered in different OncoPanel versions
View article: Supplementary Figure S4 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S4 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
RTK fusions detected in the pancreatic cancer cohort via both DNA-based and RNA-based analyses
View article: Supplementary Figure S10 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S10 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Additional clinicopathologic/genomic data for KRAS WT patient with SLC4A4-ROS1 fusion
View article: Supplementary Figure S7 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S7 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Copy number gains in MAPK genes are infrequent in KRAS WT, MAPK Negative pancreatic cancer
View article: Supplementary Figure S9 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S9 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Dual pan-RAF and MEK inhibition demonstrates synergistic inhibition of pancreatic cancer PDOs harboring BRAF in-frame deletions
View article: Supplementary Table S6 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S6 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Mutational frequency KRAS WT vs KRAS MUT
View article: Supplementary Figure S3 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S3 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Focal chromosomal alterations and oncogenic drivers differ between KRAS WT and mutant pancreatic cancer
View article: Supplementary Table S16 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S16 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Mutational Profile of BRAF in frame deleted organoid cases
View article: Supplementary Table S7 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S7 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
MMR-D cases
View article: Supplementary Figure S10 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S10 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Additional clinicopathologic/genomic data for KRAS WT patient with SLC4A4-ROS1 fusion
View article: Supplementary Table S17 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S17 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Clinical-Genomic Characteristics Of Early Onset (Age <45) KRAS WT Pancreatic Cancer
View article: Supplementary Table S5 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S5 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
TP53 hotspot variant distribution
View article: Supplementary Figure S5 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S5 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Pathway-level comparison reveals enrichment of alternative MAPK alterations in KRAS WT pancreatic cancer
View article: Supplementary Figure S8 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Figure S8 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
Germline genetic analysis of KRAS WT versus KRAS mutant pancreatic cancer